Advanced search
Publication Cover
Infectious Diseases Volume 55, 2023 - Issue 4
Submit an article Journal homepage
191
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

In vitro susceptibility of carbapenem resistant Enterobacterales to meropenem-vaborbactam and ceftazidime-avibactam at a single academic medical centre

Jenna Adamsa Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USACorrespondence[email protected]
View further author information
,
Maressa Santarossaa Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USA;b Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USAView further author information
,
Amanda Harringtonc Department of Pathology and Laboratory Medicine, Loyola University Chicago, Maywood, IL, USAView further author information
,
Michael Bauerc Department of Pathology and Laboratory Medicine, Loyola University Chicago, Maywood, IL, USAView further author information
,
Amy Wozniakd Clinical Research Office, Loyola University of Chicago, Chicago, IL, USAView further author information
,
Laurie Labuszewskia Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USAView further author information
&
Fritzie S. Albarillob Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USAORCID Iconhttps://orcid.org/0000-0002-3441-301XView further author information
ORCID Icon show all
Pages 282-291 | Received 08 Dec 2021, Accepted 02 Feb 2023, Published online: 10 Feb 2023

References

  • Centers for Disease Control and Prevention [Internet]. Antibiotic/antimicrobial resistance. Biggest threats and data: 2019 AR Threats Report; 2019a Available from: https://www.cdc.gov/drugresistance/biggest-threats.html.
  • Centers for Disease Control and Prevention [Internet]. Healthcare-associated infections. Clinicians: Information about CRE; 2019b Available from: https://www.cdc.gov/hai/organisms/cre/cre-clinicians.html.
  • Allergan Inc.. Avycaz (ceftazidime and avibactam) prescribing information; 2019. Avaialble from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf.
  • Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacterales infections. Clin Infect Dis. 2016;63:1615–1618.
  • Melinta Therapeutics, LLC.. Vabomere (meropenem and vaborbactam) prescribing information; 2019. Avaialble from: http://www.vabomere.com/media/pdf/vabomere-us-prescribing-information.pdf.
  • Pfizer Laboratories Inc. Merrem IV (meropenem) prescribing information; 2019. Avaialble from: https://www.pfizer.com/products/product-detail/merrem_i_v.
  • Petty LA, Henig O, Patel TS, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacterales. Infect Drug Resis. 2018;11:1461–1472.
  • Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097-16.
  • van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
  • Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing: twenty-ninth informational supplement M100., Wayne, PA, USA: CLSI.
  • Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883-17.
  • Volpicelli L, Venditti M, Ceccarelli G, et al. Place in therapy of the newly available armamentarium for multi-drug-resistant gram-negative pathogens: proposal of a prescription algorithm. Antibiotics. 2021;10:1475.
  • Wilson WR, Kline EG, Jones CE, et al. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant enterobacterales. Antimicrob Agents Chemother. 2019;63:e02048-18.
  • Kuti J. Optimizing antimicrobial pharmacodynamics: a guide for your stewardship program. Rev Med Clin Condes. 2016;27:615–624.
  • Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
  • Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistanct Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62:e02497-17.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.